PRP and polynucleotides for hair loss: clinical distinction

PRP is made from a person’s own blood and is used to deliver a platelet-rich fraction to the scalp. Polynucleotides are DNA fragments supplied as an injectable material. They are not substitutes: PRP has more direct study in pattern hair loss, while polynucleotide evidence for hair outcomes remains less settled.

The distinction in one clinical decision

PRP and polynucleotides are both discussed as scalp injectables, but they begin with different materials, have different practical demands and rest on different bodies of evidence. Treating them as interchangeable because both are injected into the scalp removes the question that matters most: what is causing the hair change?

Platelet-rich plasma, usually shortened to PRP, is prepared from a sample of the patient’s blood. A preparation process concentrates a platelet-containing fraction before it is injected. The proposed rationale is that platelets release signalling molecules involved in tissue repair and cell communication. Evidence status: published clinical trials and systematic reviews exist for PRP in androgenetic alopecia, but methods and outcome measures vary.

Polynucleotides, often shortened to PN, are fragments of DNA used in injectable preparations. Their proposed role is not to replace a missing hormone, reverse an autoimmune disorder or create new follicles. In scalp discussions, they are generally presented as a way to support the local tissue environment. Evidence status: direct, high-quality evidence for polynucleotides as a hair-loss treatment is substantially less established than the PRP literature.

A defensible consultation therefore starts with a diagnosis, not a menu of injectable options. Pattern hair loss, a sudden shedding episode, scalp inflammation, patchy loss and hair-shaft breakage can look similar in photographs while requiring very different next steps. An injection may be considered only after the clinician has identified the likely process and explained what the proposed treatment can, and cannot, address.

Neither injectable is a substitute for investigating a new, rapid or unexplained change in hair density. Evidence status: diagnostic assessment is required because hair loss has multiple causes with different medical implications.

What PRP is doing, and where it may fit

PRP is an autologous treatment, meaning the material starts with the patient’s own blood. A clinician takes blood, processes it using the selected system and injects the resulting platelet-containing preparation into planned scalp areas. The exact composition can differ between systems and between patients. Platelet concentration, white-cell content, activation method, injection depth and treatment interval are not standardised across the research literature.

The clinical literature for PRP is most often discussed in relation to androgenetic alopecia, also called pattern hair loss. This is the progressive, patterned miniaturisation of hair follicles that commonly affects the frontal scalp, crown or central parting. Some trials report changes in measures such as hair density, but differences in protocol and follow-up mean an individual result cannot be inferred from a study average. Evidence status: the PRP evidence base is suggestive for pattern hair loss, not a guarantee of visible regrowth for an individual.

PRP is less straightforward where the diagnosis is uncertain. Diffuse shedding may reflect telogen effluvium, which can follow illness, medication changes, nutritional deficiency, endocrine change or physiological stress. Patchy loss can require assessment for alopecia areata. Pain, scale, pustules, marked redness or loss of follicular openings can indicate an inflammatory or scarring disorder requiring prompt medical review. In these situations, PRP should not displace diagnostic work-up or disease-specific treatment.

The blood draw and preparation are practical distinctions. A person considering PRP should be told whether they have relevant blood disorders, use medicines that affect bleeding or platelet function, or have an active scalp infection. These factors may change whether the procedure is appropriate or how it is planned. Evidence status: individual suitability depends on medical history and procedural risk assessment.

What polynucleotides are doing, and where the evidence stops

Polynucleotide injections use supplied DNA fragments rather than a preparation made from the patient’s blood. The material is commonly discussed in aesthetic medicine in relation to tissue quality and repair signalling. That broad rationale does not itself establish a role in treating a particular form of hair loss.

For a scalp patient, the key distinction is that a polynucleotide course should not be described as equivalent to PRP merely because both may be offered through a series of injections. The material, the proposed mechanism and the amount of direct hair-loss evidence differ. The clinical question is not whether polynucleotides are biologically active in a laboratory or in other tissues. It is whether a particular preparation, protocol and patient group have been studied for the hair-loss outcome being promised.

Evidence status: laboratory findings and evidence from non-scalp uses cannot by themselves establish effectiveness for hair loss. A clinic should separate those categories clearly. It should also state whether it is relying on direct studies in people with the same hair-loss pattern, or on an extrapolation from skin-focused evidence.

Polynucleotides may be discussed when the treatment aim is framed around scalp tissue condition rather than as a primary treatment for follicle miniaturisation. Even then, the patient needs a clear account of the uncertainty. There is no basis for assuming that improved skin hydration, comfort or appearance necessarily changes follicle biology or long-term hair density.

Where a product is derived from fish, sourcing and allergy history require specific discussion. The product instructions and the clinician’s assessment matter more than a general statement that a material is natural or compatible. Evidence status: source material and contraindications are product-specific.

Which hair-loss presentations change the choice

The first branch in the decision is whether there is a working diagnosis. A gradual patterned change with preserved scalp skin may lead to a discussion of PRP as an adjunctive option, while retaining the uncertainty created by varied protocols. A polynucleotide discussion needs a separate rationale and should not borrow PRP’s evidence as though it were its own.

This is a decision rule rather than a self-diagnosis tool. A clinician may use scalp examination, history and, where indicated, dermoscopy or medical investigation. Evidence status: injectable choice follows diagnosis; it does not establish diagnosis.

What a course realistically involves

Both options normally involve planned sessions rather than a one-off procedure. However, there is no universal schedule that can be transferred from one PRP study, clinic protocol or polynucleotide product to every person. A sound plan names the intended treatment area, the rationale, the review point and the criteria for stopping or changing course.

PRP adds the stages of blood collection and processing before injection. Its practical burden includes the possibility that the preparation differs according to the equipment and protocol used. Polynucleotides remove the blood-draw stage but introduce questions about the specific supplied material, including source, traceability and instructions for use. Both involve needle-related risks, including pain, bruising, swelling, bleeding and infection. Evidence status: injection risk is procedural and does not disappear because a material is autologous or naturally derived.

A review should be based on the same baseline record, scalp examination and agreed outcome measure, rather than casual comparison of differently lit photographs. It should also include a route for reporting a reaction or unexpected deterioration. If the initial diagnosis becomes less convincing, the appropriate response is reassessment, not simply adding more sessions.

Clinics that offer both have to make that choice in front of the patient rather than in theory: Halcyon Medispa in London, for instance, runs PRP hair treatment in London alongside polynucleotide courses under its medical director, and decides between them on the pattern and stage of the loss.

That sort of choice should be documented in terms a patient can check: why this material, why now, what evidence applies, what alternative clinical assessment is needed and what would count as a reason not to continue.

Can PRP and polynucleotides be used together?

They can be proposed together, but a combined proposal requires more explanation, not less. Combining two injectables does not automatically combine their evidence. A patient should ask whether the proposed sequence has been tested for the same hair-loss presentation, whether outcomes can be attributed to either element and what added procedural risk or burden the second intervention introduces.

There may be a clinical rationale to address more than one concern, such as a diagnosed pattern of hair loss alongside a separate scalp-skin concern. But those concerns should be named separately. A vague account that both treatments “stimulate” the scalp is not enough to show why both are necessary. Evidence status: a biological rationale is not the same as comparative clinical evidence for a combined protocol.

A useful decision rule is simple: use one intervention where its purpose, evidence and review criteria can be stated; add another only where it addresses a separately defined problem and the uncertainty has been explained. If neither intervention changes the clinical priority, such as active inflammatory disease or a need to investigate sudden shedding, neither should be used to postpone that priority.

Patients should also distinguish a package from a treatment plan. A package describes a commercial arrangement. A treatment plan records a diagnosis or working diagnosis, the intervention, the evidence limits, foreseeable risks, alternatives and a review decision. The latter is the document that allows a patient to understand whether PRP, PN, both or neither makes clinical sense.

Limits of this distinction

This reference does not diagnose hair loss, recommend a product or decide whether any individual should receive an injection. It does not cover exosome or vesicle treatments, which are a separate scientific and regulatory subject. It also does not replace examination by an appropriately qualified clinician when hair loss is new, rapid, patchy, symptomatic or accompanied by a change in general health.

The discussion applies to the clinical distinction between PRP and polynucleotide injectables for scalp and hair-loss conversations. It does not establish that either treatment is suitable for pregnancy, breastfeeding, children, people with blood or immune disorders, people taking medicines that affect bleeding, or people with an active scalp condition. Those decisions depend on personal medical history, the specific material and the clinician’s assessment.

Evidence in this area changes as studies are published, but not all studies answer the same question. A small uncontrolled series, a laboratory experiment, a study in facial skin and a randomised trial in people with androgenetic alopecia carry different weight. The crucial unanswered questions include which PRP preparation is optimal, which patients are most likely to benefit, how durable any effect is, and whether polynucleotide protocols produce reproducible hair-specific outcomes. Evidence status: these open questions limit any claim of predictable individual regrowth.